MedTrace Logo

Durvalumab in DLBCL After Autologous Transplant

NCT03241017 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-04-09

No results posted yet for this study

Summary

The trial assess the progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG

Durvalumab

Immunotherapy with Durvalumab after ASCT

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Thomas Pabst, MD · Departement of Medical Oncology, University Hospital Berne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2021-10-31
Completion
2021-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03241017 on ClinicalTrials.gov